



Newsroom

Lupin Receives Tentative Approval for Generic Prezista® Tablets

Mumbai, Baltimore, December 30, 2014: Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg and 800 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Janssen Products, LP (Janssen) Prezista® Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg.

Lupin's Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg are the AB-rated generic equivalents of Janssen's Prezista® tablets and are indicated Lupin's Darunavir Tablets is indicated for the treatment of HIV-1 infections.

Prezista® Tablets had annual U.S sales of US\$ 1.2 billion (IMS MAT September, 2014).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364 million (USD 304 million) respectively. Please visit <http://www.lupin.com> for more information.

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

About Lupin Pharmaceuticals Inc.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, please do visit <http://www.lupinpharmaceuticals.com>

You could also follow us on Twitter - www.twitter.com/lupinlimited

**For more information, please contact - Shamsheer Gorawara
Head – Corporate Communications**

Ph: +91- 98 20 338 555

Email: shamsheergorawara@lupinpharma.com

Or

Alpesh Dalal
Head - M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupinpharma.com

Safe Harbor Statement *

**Prezista® is a registered trademark of Tibotec
Pharmaceuticals.**